CIK 0001628171 · Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472029180
- Phone
- 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,886,888
- in 2 filings, $6.9M under 10b5-1 plans
Net −$6,886,888. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Anders Jack Chief Financial Officer | Option exercise 10b5-1 | +15,900 | $42.45 | $675K | 135,116 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Option exercise 10b5-1 | +19,850 | $18.56 | $368K | 154,966 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −3,499 | $181.04 | $633K | 151,467 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −5,776 | $182.09 | $1.1M | 145,691 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −2,700 | $182.87 | $494K | 142,991 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −1,900 | $184.02 | $350K | 141,091 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −800 | $185.04 | $148K | 140,291 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −400 | $186.41 | $75K | 139,891 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −600 | $187.34 | $112K | 139,291 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −200 | $189.17 | $38K | 139,091 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −500 | $190.99 | $95K | 138,591 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −9,486 | $191.94 | $1.8M | 129,105 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −9,889 | $192.84 | $1.9M | 119,216 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,900 | $42.45 | $675K | 0 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,850 | $18.56 | $368K | 750 |
| 2026-11-11 | Borisy Alexis Director | Gift | −10,625 | 2,329,450 | ||
| 2026-11-09 | Mancini Anthony See Remarks | Option exercise 10b5-1 | +810 | $33.62 | $27K | 40,575 |
| 2026-11-09 | Mancini Anthony See Remarks | Option exercise 10b5-1 | +1 | $102.02 | $102 | 40,576 |
| 2026-11-09 | Mancini Anthony See Remarks | Sale 10b5-1 | −811 | $200.00 | $162K | 39,765 |
| 2026-11-09 | Mancini Anthony See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −810 | 90,505 |
Page 1 of 2 · 21 trades